Back to results
US 2009/0214521 A1Published application
Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
OwnerJohn Langenfeldinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerJohn Langenfeldinventor
Estimating the term…
The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such inhibition may be accomplished by ligands or antibodies that bind to BMP-2 or BMP-2 receptors. It may also be achieved by preventing the processing of pro-BMP-2, or blocking transcription or replication of BMP-2 DNA or translation of BMP-2 mRNA. The diagnostic component of the invention involves measuring the BMP-2 level in biological samples from both a patient and a subject and comparing those levels. Elevated levels of BMP-2 in the patient compared to the non-cancerous subject indicate cancer.
A method of reducing vascularization of a bone morphogenetic protein-2 overexpressing lung tumor in a subject comprising administering to a subject in need of treatment a therapeutically effective amount of a bone morphogenetic protein-2 (BMP-2) activity inhibitor thereby reducing vascularization of a BMP-2 overexpressing lung tumor in the subject.
Dependencies are inferred from the claim text.